MRE Porton Down

Porton Biopharma is a specialized biopharmaceutical company based at the historic Porton Down site in Wiltshire, England. Established in 2015 as a spin-out from Public Health England, the company commercializes the research and manufacturing capabilities originally developed by the Microbiological Research Establishment (MRE). Its core portfolio includes Erwinase, a treatment for acute lymphoblastic leukemia, and the UK's licensed anthrax vaccine. The company also provides contract development and manufacturing services, notably producing the botulinum toxin for Ipsen's Dysport. Porton Biopharma remains wholly owned by the UK government's Department of Health and Social Care, focusing on global health security and niche therapeutic markets.